TNNI3 and COVID-19: In a paper responding to the AHA guidelines regarding use of these biomarkers in COVID-19 patients, Chapman et al. [3] published a statement of strong support for the value of determinations of serum cTnI and cTnT as biomarkers for cardiac injury in SARS-CoV-2 infected patients, who are older with coronary syndromes, demand ischemia, and inflammation.